### FRIDAY, SEPTEMBER 6

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 p.m.-7:40 p.m.</td>
<td><strong>WELCOME AND KEYNOTE LECTURES</strong>&lt;br&gt;&lt;br&gt;Session Chair: Brian M. Wolpin, Dana-Farber Cancer Institute, Boston, MA</td>
<td>America North and Center Ballroom</td>
</tr>
<tr>
<td>6:00 p.m.-6:10 p.m.</td>
<td><strong>Welcome from Cochairs</strong></td>
<td></td>
</tr>
<tr>
<td>6:10 p.m.-6:20 p.m.</td>
<td><strong>Welcome from Lead Supporters</strong>&lt;br&gt;&lt;br&gt;Kerri Kaplan, Lustgarten Foundation, Woodbury, NY&lt;br&gt;Julie Fleshman, Pancreatic Cancer Action Network, Manhattan Beach, CA</td>
<td></td>
</tr>
<tr>
<td>6:20 p.m.-7:00 p.m.</td>
<td><strong>Rising Star Keynote</strong>&lt;br&gt;&lt;br&gt;Mechanisms and consequences of pancreatic cancer stromal evolution&lt;br&gt;&lt;br&gt;Mara Sherman, Oregon Health Sciences University, Portland, OR</td>
<td></td>
</tr>
<tr>
<td>7:00 p.m.-7:40 p.m.</td>
<td><strong>Opening Keynote</strong>&lt;br&gt;&lt;br&gt;Targeting innate immunity in pancreatic carcinoma&lt;br&gt;&lt;br&gt;George Miller, Perlmutter Cancer Center, New York University Langone Medical Center, New York, NY</td>
<td></td>
</tr>
<tr>
<td>7:45 p.m.-10:00 p.m.</td>
<td><strong>OPENING RECEPTION / POSTER SESSION A</strong>&lt;br&gt;&lt;br&gt;American Ballroom South and Staffordshire Ballroom</td>
<td></td>
</tr>
</tbody>
</table>

### SATURDAY, SEPTEMBER 7

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 a.m.-8:30 a.m.</td>
<td><strong>BREAKFAST AND NETWORKING ROUNDTABLES</strong>&lt;br&gt;&lt;br&gt;American Ballroom South&lt;br&gt;&lt;br&gt;1. Dafna Bar-Sagi&lt;br&gt;2. Stephanie Dougan&lt;br&gt;3. Elizabeth M. Jaffee&lt;br&gt;4. Christine A. Iacobuzio-Donahue</td>
<td></td>
</tr>
<tr>
<td>8:30 a.m.-10:30 a.m.</td>
<td><strong>PLENARY SESSION 1: TUMOR MICROENVIRONMENT</strong>&lt;br&gt;&lt;br&gt;America North and Center Ballroom&lt;br&gt;&lt;br&gt;Session Chair: Ben Z. Stanger, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA</td>
<td></td>
</tr>
<tr>
<td>8:30 a.m.-8:55 a.m.</td>
<td><strong>Immune contexture of primary and metastatic pancreatic cancer</strong>&lt;br&gt;&lt;br&gt;Lisa Coussens, Oregon Health Sciences University, Portland, OR</td>
<td></td>
</tr>
<tr>
<td>8:55 a.m.-9:20 a.m.</td>
<td><strong>Regulatory T-cell depletion causes compensatory immune suppression and accelerates pancreatic carcinogenesis</strong>&lt;br&gt;&lt;br&gt;Marina Pasca Di Magliano, University of Michigan, Ann Arbor, MI</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
</tr>
<tr>
<td>--------------------</td>
<td>------------------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| 9:20 a.m.-9:45 a.m.| **Heterocellular interactions in the tumor microenvironment shape tumor**  
                        | cell signaling                                                         |
|                   | Claus Jorgensen, Cancer Research UK Manchester Centre, Manchester,       |
|                   | United Kingdom                                                        |
| 9:45 a.m.-10:00 a.m.| **Senescence induction triggers vascular remodeling and new vulnerabilities to**  
                        | chemo- and immunotherapy in pancreas cancer*                           |
|                   | Marcus Ruscetti, Memorial Sloan Kettering Cancer Center, New York, NY    |
| 10:10 a.m.-10:15 a.m.| **Discussion**                                                          |
| 10:15 a.m.-10:45 a.m.| **BREAK**                                                              |
|                   | American Ballroom Foyer                                               |
| 10:45 a.m.-12:30 p.m.| **PLENARY SESSION 2: GENOMICS**                                       |
|                   | America North and Center Ballroom                                      |
|                   | **Session Chair:** Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA |
| 10:45 a.m.-11:10 a.m.| **Clonal evolution and progression of pancreatic cancer precursor lesions** |
|                   | Laura DeLong Wood, Johns Hopkins University, Baltimore, MD             |
| 11:10 a.m.-11:35 a.m.| **Multimodal evolutionary dynamics of pancreatic cancer**               |
|                   | Christine A. Iacobuzio-Donahue, Memorial Sloan Kettering Cancer Center, New York, NY |
| 11:35 a.m.-12:00 p.m.| **Molecular subtypes—bench to bedside**                               |
|                   | Jen Jen Yeh, University of North Carolina-Chapel Hill, Chapel Hill, NC |
| 12:00 p.m.-12:15 p.m.| **Loss of TET2 activity results in epigenetic instability and drives PDAC**  
                        | molecular subtypes*                                                    |
|                   | Eric O’Neill, University of Oxford, Oxford, United Kingdom            |
| 12:15 p.m.-12:30 p.m.| **A novel deaminase independent function of APOBEC3A catalyzes widespread**  
                        | chromosomal instability to drive an aggressive metastatic phenotype in**  
                        | pancreatic cancer*                                                    |
|                   | Sonja Woermann, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 12:30 p.m.-12:45 p.m.| **Discussion**                                                          |
| 12:45 p.m.-3:30 p.m.| **POSTER SESSION B / LUNCH**                                          |
|                   | Staffordshire Ballroom                                                 |

*Short talk from proffered abstract*
CONFERENCE PROGRAM

3:30 p.m.–5:30 p.m.  PLENARY SESSION 3: IMMUNOLOGY  
America North and Center Ballroom  
Session Chair: Elizabeth M. Jaffee, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD  
3:30 p.m.–3:55 p.m.  Tumor-specific T cells reprogram mononuclear phagocytes for destruction of checkpoint blockade-resistant pancreatic cancer  
Stephanie Dougan, Dana-Farber Cancer Institute, Boston, MA  
3:55 p.m.–4:20 p.m.  Immune cell signaling in human and mouse pancreas cancer  
Aida Habtezion, Stanford University, Stanford, CA  
4:20 p.m.–4:45 p.m.  Targeting pancreatic cancer with TCR-engineered T cells  
Phil Greenberg, Fred Hutchinson Cancer Research Center, Seattle, WA  
4:45 p.m.–5:00 p.m.  STING and TLR-independent activation of T-cell responses against pancreatic cancer using agonistic CD40 antibody*  
Katelyn Byrne, University of Pennsylvania, Philadelphia, PA  
5:00 p.m.–5:15 p.m.  Autophagy facilitates immune evasion of pancreatic cancer through downregulation of MHC class I molecules*  
Keisuke Yamamoto, New York University School of Medicine, New York, NY  
5:15 p.m.–5:30 p.m.  Discussion  
5:30 p.m.  EVENING OFF / DINNER ON OWN

SUNDAY, SEPTEMBER 8

7:30 a.m.–8:30 a.m.  BREAKFAST AND NETWORKING ROUNDTABLES  
American Ballroom South  
1. Dafna Bar-Sagi  
2. Lisa Coussens  
3. Brian Wolpin  
4. Rosie Sears  
5. Robert H. Vonderheide  
8:30 a.m.–10:30 a.m.  PLENARY SESSION 4: EARLY-STAGE TRIALS AND NOVEL TREATMENT COMBINATIONS  
America North and Center Ballroom  
Session Chair: Luis A. Diaz, Memorial Sloan Kettering Cancer Center, New York, NY  
8:30 a.m.–8:55 a.m.  CD40 immunotherapy for pancreatic cancer  
Robert H. Vonderheide, University of Pennsylvania, Philadelphia, PA

*Short talk from proffered abstract
8:55 a.m.-9:20 a.m.  
Modulating the immune response with epigenetic agents  
Nilofer Azad, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

9:20 a.m.-9:45 a.m.  
Polymerase theta synthetic lethal interaction in homologous recombination-deficient pancreatic ductal adenocarcinoma  
Diane Simeone, New York University, New York, NY

9:45 a.m.-10:00 a.m.  
Multimodal mapping of the tumor microenvironment in pancreatic ductal adenocarcinoma*  
Eileen Carpenter, University of Michigan, Ann Arbor, MI

10:00 a.m.-10:15 a.m.  
Phase I/II study of mesothelin-targeted immunotoxin LMB-100 with nab-paclitaxel for patients with advanced pancreatic adenocarcinoma*  
Christine Alewine, National Cancer Institute, Bethesda, MD

10:15 a.m.-10:30 a.m.  
Intratumoral T-cell distribution in murine and patient pancreatic cancer correlates with tissue heterogeneity and survival*  
Julienne Carstens, The University of Texas MD Anderson Cancer Center, Houston, TX

10:30 a.m.-10:45 a.m.  
BREAK  
American Ballroom Foyer

10:45 a.m.-12:30 p.m.  
PLENARY SESSION 5: RAS AND ONCOGENE SIGNALING  
America North and Center Ballroom  
Session Chair: Dafna Bar-Sagi, New York University Langone Medical Center, New York, NY

10:45 a.m.-11:10 a.m.  
Deciphering the origins of PDAC development  
Laura Attardi, Stanford University, Stanford, CA

11:10 a.m.-11:35 a.m.  
KRAS and environmental signals regulate MYC to drive lineage plasticity, pancreas cancer progression, and therapeutic resistance  
Rosalie Sears, Oregon Health Sciences University, Portland, OR

11:35 a.m.-12:00 p.m.  
Genomic loss of the wild-type KRAS allele in pancreatic tumor progression and metastasis  
Gloria H. Su, Columbia University, New York, NY

12:00 p.m.-12:15 p.m.  
KRas modulates pancreatic cancer cell metabolism and invasive potential through the lipase HSL*  
Cody Rozeveld, Mayo Clinic, Rochester, MN

12:15 p.m.-12:30 p.m.  
Enhancing the effect of autophagy inhibition for pancreatic cancer treatment*  
Kirsten Bryant, University of North Carolina at Chapel Hill, Chapel Hill, NC

12:30 p.m.-12:45 p.m.  
Discussion

12:45 p.m.-2:00 p.m.  
LUNCH ON OWN

*Short talk from proffered abstract
CONFERENCE PROGRAM

2:00 p.m.–4:00 p.m.  PLENARY SESSION 6: PREVENTION AND EARLY DETECTION
America North and Center Ballroom

Session Chair: Anirban Maitra, The University of Texas MD Anderson Cancer Center, Houston, TX

2:00 p.m.-2:25 p.m.  Retooling a blood-based biomarker into a theranostic agent
Jason Lewis, Memorial Sloan Kettering Cancer Center, New York, NY

2:25 p.m.-2:50 p.m.  Early detection of pancreatic cancer—challenges and opportunities
Anirban Maitra

2:50 p.m.-3:15 p.m.  Circulating tumor DNA in cancer diagnosis—challenges and potential
Anne Marie O’Broin Lennon, Johns Hopkins University, Baltimore, MD

3:15 p.m.-3:30 p.m.  Evaluation of the implementation of genetic cancer screening guidelines in African-American pancreatic cancer patients in a safety net hospital*
Taiwo Ajose, Morehouse School of Medicine, Atlanta, GA

3:30 p.m.-3:45 p.m.  The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice*
Dannielle Engle, Salk Institute for Biological Studies, La Jolla, CA

3:45 p.m.-4:00 p.m.  Discussion

4:00 p.m.–6:30 p.m.  POSTER SESSION C / RECEPTION
Staffordshire Ballroom

MONDAY, SEPTEMBER 9

7:00 a.m.–8:00 a.m.  BREAKFAST
American Ballroom South

8:00 a.m.-9:45 a.m.  PLENARY SESSION 7: METABOLISM
America North and Center Ballroom

Session Chair: Alec Kimmelman, New York University, New York, NY

8:00 a.m.-8:25 a.m.  Understanding metabolic limitations in pancreatic cancer
Matthew Vander Heiden, Massachusetts Institute of Technology, Cambridge, MA

8:25 a.m.-8:50 a.m.  New players and unique features of cancer lysosomes
Rushika Perera, University of California San Francisco, San Francisco, CA

8:50 a.m.-9:15 a.m.  Identifying metabolic dependencies in pancreatic cancer
Alec Kimmelman

9:15 a.m.-9:30 a.m.  Targeting macrophage metabolism to improve therapy in pancreatic cancer*
Christopher Halbrook, University of Michigan, Ann Arbor, MI

9:30 a.m.-9:45 a.m.  Discussion

*Short talk from proffered abstract
9:45 a.m.-10:00 a.m.  BREAK
American Ballroom Foyer

10:00 a.m.-11:45 a.m.  PLENARY SESSION 8: NEW MODELS SYSTEMS, ANIMALS, AND BEYOND
America North and Center Ballroom

 Session Chair: Tyler Jacks, Massachusetts Institute of Technology, Cambridge, MA

10:00 a.m.-10:25 a.m.  Title to be announced
Tyler Jacks

10:25 a.m.-10:50 a.m.  Understanding and exploiting natural barriers to pancreatic tumorigenesis
Scott Lowe, Memorial Sloan Kettering Cancer Center, New York, NY

10:50 a.m.-11:15 a.m.  Investigating the immune microenvironment in mouse models of pancreatic cancer
Jen P. Morton, Beatson Institute for Cancer Research, Glasgow, United Kingdom

11:15 a.m.-11:30 a.m.  Preclinical models to dissect immune escape in pancreatic cancer*
William Freed-Pastor, Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

11:30 a.m.-11:45 a.m.  Assessment of tumor heterogeneity, clonal evolution, and the stromal microenvironment in metastatic pancreatic ductal adenocarcinoma and matched patient-derived organoids*
Srivatsan Raghavan, Dana-Farber Cancer Institute, Boston, MA

11:45 a.m.-12:30 p.m.  CLOSING KEYNOTE
America North and Center Ballroom

 Pancreatic cancer immunotherapy: Moving forward
Dung Thi Le, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

12:30 p.m.-12:45 p.m.  CLOSING REMARKS
America North and Center Ballroom

12:45 p.m.  DEPARTURE

*Short talk from proffered abstract